Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.

Trial Details

NCT ID
NCT06930755
Phase
PHASE1
Sponsor
Nerviano Medical Sciences
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • NMS-03305293
  • Topotecan
Locations (sample)
  • Peoria, Illinois, United States|40.69365,-89.58899
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Histologically confirmed diagnosis of high-grade serous epithelial ovarian, fallopian tube or peritoneal cancer. Sponsor might opt to restrict enro…
  • Patients must have received no more than 5 prior lines of therapy and failed all evidence based local standards of care as per Investigator judgmen…
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Patient must have progressed radiographically on or after their most recent line of anticancer therapy and have measurable disease as defined by Re…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →